Peptic Ulcer Clinical Trial
Official title:
Residual Gastric Volume Measured by Upper Digestive Endoscopy 2h After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein. A Controlled, Randomized Clinical Trial
Carbohydrate enriched-drinks has been used as preoperative treatment up to two hours before anesthesia. These drinks are safe and are not associated to bronchial aspiration during anesthesia. The addition of protein may be beneficial for metabolic preconditioning but there is a few data in literature testing these drinks for safety. The aim of the study will be to investigate the residual gastric volume (RGV) measured during the gastroscopy with abbreviation of fast to 2h with a carbohydrate plus whey protein enriched-drink.
The use of carbohydrate-rich beverage in the immediate preoperative period is not only safe,
but may also reduce the catabolic stress response, nausea, vomiting, and thus enhance
postoperative recovery.The addition of protein may increase the benefits but there are few
studies on this matter. Several studies have also shown the nutritional qualities of soluble
whey proteins. Whey protein contains a high level of essential amino acids especially
branched-chain amino acids. The digestibility and gastric emptying is accelerated when
compared to casein. We thought that gastroscopy would be an excellent model to test the
gastric emptying of such drinks before testing it for elective operations. Thus, the aim of
the study will be to investigate the residual gastric volume (RGV) measured during the
gastroscopy with abbreviation of fast to 2h with a carbohydrate- whey protein-drink.
Methods A group of adult patients (age ranging from 18 to 72years-old) scheduled to
undergoing upper digestive endoscopy for diagnostic purposes due to epigastric burning at
Gastroclinica, Cuiabá, Brazil will be eligible for inclusion in this trial. Exclusion
criteria will be: American Society of Anesthesiologists (ASA) score above II, diabetes
mellitus, pregnancy, renal or hepatic failure, gastroesophageal reflux, morbid obesity (BMI
above 40 kg/m2,acute cholecystitis, use of corticosteroids up to 6 months previously, use of
any prokinetic drug up to 6 weeks, and any noncompliance or violation on the assigned
protocol of preoperative fasting. The local ethics committee approved the study, and all
patients will authorize his/her inclusion in the study by written informed consent.
Randomization A staff not involved with the study will proceed with the randomization
process. A computer program will generate random numbers to assign patients to the two
groups. Patients will be randomized to receive either conventional preoperative fasting of 8
hours (fasted group, n=15) or will receive instruction to 2 hours fast (study group, n=15).
Patients belonging to study group will fast for solids for 8h and will drink 200mL of a
beverage containing maltodextrine in addition to whey protein (Fresubin Jucy, Fresenius
Kabi, Brazil) 2 hours before the initiation of sedation with propofol for the endoscopic
exam.
Fasting protocol All patients will receive both oral and written information about the
protocol at the outpatient clinic. Endoscopies will be scheduled to begin at 8:00 AM. The
evening before operation patients will be free to ingest solid food until 11:00 PM. The
patients belonging to the abbreviation of fasting will receive written instructions to
ingest the above beverage at 6:00 AM (200 mL), and be at the Gastroclinica unit at 7:00 AM.
Endoscopy protocol Endoscopy will be performed by a certified gastroenterologist staff as
routine. Special attention will be done for RGV. The finding of any residual gastric
contents will mean that the content will be aspirate and measured. The RGV measured in mL
will be the main outcome measure of the study.
Outcome variable and statistical analysis The main endpoint of the study was the RGV.
Comparison of RGV between the two groups will be done by either Student t test or
Mann-Whitney test. A 5% will be established as significant level.
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT00471029 -
Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer
|
Phase 4 | |
Completed |
NCT00152399 -
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
|
Phase 2 | |
Not yet recruiting |
NCT02961296 -
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
|
N/A | |
Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
Completed |
NCT02342470 -
Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users
|
Phase 2 | |
Completed |
NCT02296021 -
Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT00977678 -
Drop in Gastroscopy - Experience After 9 Months
|
N/A | |
Terminated |
NCT04025983 -
Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection
|
N/A | |
Recruiting |
NCT03868267 -
Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
|
||
Completed |
NCT05237115 -
Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Completed |
NCT01667718 -
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
|
Phase 4 | |
Not yet recruiting |
NCT04784910 -
Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer
|
Phase 3 | |
Recruiting |
NCT02436018 -
WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy
|
N/A | |
Completed |
NCT03367897 -
Bleeding Ulcer and Erosions Study "BLUE Study"
|
||
Active, not recruiting |
NCT02001727 -
HEP-FYN 12-Years Follow-up
|
N/A | |
Completed |
NCT01376414 -
H. Pylori Testing for Patients With Non-specific Upper Abdominal Pain in the Emergency Department
|
N/A | |
Completed |
NCT01667692 -
Aizthromycin or Clarithromycin in H-pylori Eradication Regimen
|
Phase 4 | |
Completed |
NCT01080326 -
Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus
|
N/A | |
Completed |
NCT02536989 -
Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot
|
Phase 4 | |
Completed |
NCT00920400 -
Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract
|
N/A |